Suppression of cellular invasion by glybenclamide through inhibited secretion of platelet-derived growth factor in ovarian clear cell carcinoma ES-2 cells

FEBS Lett. 2012 May 21;586(10):1504-9. doi: 10.1016/j.febslet.2012.04.007. Epub 2012 Apr 25.

Abstract

It has been demonstrated that potassium channels (K(+) channels) play significant roles in some malignant phenotypes. Here, we provide the first evidence that treatment with glybenclamide, an ATP-sensitive K(+) channel blocker, inhibited cell migration in an ovarian clear cell carcinoma cell line, ES-2. Treatment with glybenclamide or knockdown by siRNA targeted against K(+) channel subunits demonstrated the suppression of ovarian cancer cell invasion, which occurred via inhibition of PDGF-AA secretion. Therefore, our findings suggest that K(+) channel blockers may be useful chemotherapeutic drugs for blocking the invasiveness of ovarian cancers.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Cell Line, Tumor
  • Enzyme-Linked Immunosorbent Assay
  • Female
  • Glyburide / pharmacology*
  • Humans
  • Ovarian Neoplasms / metabolism*
  • Ovarian Neoplasms / pathology
  • Platelet-Derived Growth Factor / antagonists & inhibitors*
  • Platelet-Derived Growth Factor / metabolism
  • Polymerase Chain Reaction
  • Potassium Channel Blockers / pharmacology

Substances

  • Platelet-Derived Growth Factor
  • Potassium Channel Blockers
  • Glyburide